Phase
Condition
Venous Thrombosis
Thrombosis
Venous Thromboembolism
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Objective diagnosis of isolate distal deep vein thrombosis within 72 hours from theevaluation for inclusion in the study and if any type of parenteral treatment wasadministered at therapeutic doses for 3 days or less (maximum accepted doses of lowmolecular weight heparin: 6 doses; of fondaparinux: 3 doses).
Exclusion
Exclusion Criteria:
Age < 18 years
Any absolute contraindication to anticoagulant treatment
Pregnancy or breast-feeding
Presence of active cancer
Concomitant presence of proximal deep vein thrombosis or pulmonary embolism
Any concomitant indication for long-term anticoagulant treatment
Creatinine clearance ≤30 ml/min, according to Cockcroft-Gault equation
Cirrhosis Child-Pugh score B or C
Liver disease associated with coagulopathy and high risk of bleeding
Any other contraindication to rivaroxaban as per local SmPC
Failure to provide written informed consent
Study Design
Connect with a study center
Ospedale di Faenza
Faenza,
ItalyActive - Recruiting
Ospedale di Padova
Padua,
ItalyActive - Recruiting
Ospedale di Pieve di Soligo
Pieve di Soligo,
ItalyActive - Recruiting
Ospedale di Reggio Emilia
Reggio Emilia,
ItalyActive - Recruiting
University of Siena
Siena,
ItalyActive - Recruiting
Ospedale di Circolo
Varese, 21100
ItalyActive - Recruiting
University Of Insubria
Varese, 21100
ItalyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.